|
28 Jan 2020 |
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
|
|
28 Jan 2020 |
Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
|
|
27 Jan 2020 |
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
|
|
27 Jan 2020 |
Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
|
|
27 Jan 2020 |
AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan
|
|
27 Jan 2020 |
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
|
|
25 Jan 2020 |
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
|
|
25 Jan 2020 |
Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress
|
|
24 Jan 2020 |
Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-Invasive Urothelial Cancer
|
|
23 Jan 2020 |
The European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Paediatric Patients With Moderate to Severe Plaque Psoriasis
|
|
23 Jan 2020 |
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
|
|
22 Jan 2020 |
Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus
|
|
22 Jan 2020 |
FDA Approves TEPEZZA (TM) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
|
|
21 Jan 2020 |
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
|
|
21 Jan 2020 |
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
|
|
21 Jan 2020 |
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
|
|
21 Jan 2020 |
Transcenta Announces Acceptance by NMPA of IND Application of a Novel Humanized Claudin 18.2 Monoclonal Antibody
|
|
21 Jan 2020 |
European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
|
|
16 Jan 2020 |
PlantForm advances HIV antibody research in collaboration with scientists funded by U.S. National Institutes of Health
|
|
15 Jan 2020 |
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
|
|
15 Jan 2020 |
New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
|
|
14 Jan 2020 |
Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase 3 Trial
|
|
13 Jan 2020 |
Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
|
|
13 Jan 2020 |
Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
|
|
13 Jan 2020 |
Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
|
